Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Novumgen Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, which means each examiner is responsible for a pending matter. This distribution of 2 distinct examiners ensures that the company's current pending workload is split between two different individual perspectives at the USPTO. Practitioners must be prepared to navigate these separate examination styles within the Biotechnology & Pharmaceuticals field.
Both pending office actions are contained within 1 distinct art unit. This indicates a focused technical and administrative scope for the company's biotechnology and pharmaceutical filings. Kamal A Saeed is the busiest examiner for the portfolio, managing 1 pending office action. This 1 action represents a portion of the total 2 pending actions currently facing the organization. The concentration in 1 distinct art unit suggests a consistent technical focus for these filings.
With 2 distinct examiners working within 1 distinct art unit, the company faces two different interpretations of the same administrative standards. Practitioners should focus on the specific policies of this 1 distinct art unit while tailoring their responses to the individual requirements of Kamal A Saeed and the other examiner involved. Managing the 2 pending office actions requires consistency in technical arguments to ensure that responses in one case do not conflict with those in another within the same administrative group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, KAMAL A | 1 | 83.9% | +9.8% |
| PETRITSCH, AMANDA MICHELLE | 1 | 57.1% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18878567 | AN ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF BACLOFEN AND ITS PROCESS OF PREPARATION | SAEED, KAMAL A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729547 | A LIQUID PHARMACEUTICAL FORMULATION OF CLONIDINE HYDROCHLORIDE | PETRITSCH, AMANDA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18878567 | AN ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF BACLOFEN AND ITS PROCESS OF PREPARATION | SAEED, KAMAL A | — | §103§112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18729547 | A LIQUID PHARMACEUTICAL FORMULATION OF CLONIDINE HYDROCHLORIDE | PETRITSCH, AMANDA MICHELLE | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Jul 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial